Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00003597




Registration number
NCT00003597
Ethics application status
Date submitted
1/11/1999
Date registered
18/04/2003
Date last updated
24/07/2014

Titles & IDs
Public title
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
Scientific title
A Phase I Study of Thrombopoietin (rhTPO) Plus G-CSF in Children Receiving Ifosfamide, Carboplatin, and Etoposide (I.C.E.) Chemotherapy for Recurrent or Refractory Solid Tumors
Secondary ID [1] 0 0
CCG-09717
Secondary ID [2] 0 0
09717
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cancer 0 0
Condition category
Condition code
Other 0 0 0 0
Research that is not of generic health relevance and not applicable to specific health categories listed above

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - recombinant human thrombopoietin
Treatment: Drugs - carboplatin
Treatment: Drugs - etoposide
Treatment: Drugs - ifosfamide
Other interventions - G-CSF

Experimental: Cohort 1 - Chemotherapy days 0-4, G-CSF (5 µg/kg/d) as a daily subcutaneous injection beginning on Day 5. All patients receive recombinant human thrombopoietin (rhTPO). rhTPO began on the last day of ICE (Ifosfamide, Carboplatin and Etoposide) chemotherapy (Day 4) and subsequent doses will be administered on Days 6, 8, 10 and 12 (5 doses total). The initial dose of rhTPO was 1.2 µg/kg/dose and was subsequently escalated to 2.4 and 3.6 µg/kg/dose as tolerated. Therapy will continue for maximum six courses. Pharmacokinetic data will be obtained (during course one only).

Experimental: Cohort 2 - Chemotherapy days 0-4, G-CSF (5 µg/kg/d) as a daily subcutaneous injection beginning on Day 5. All patients receive recombinant human thrombopoietin (rhTPO). The dose of rhTPO 1.2 µg/kg/dose and subsequently escalated to 2.4 and 3.6 µg/kg/dose as tolerated. Patients assigned to Cohort II will receive pre-chemotherapy rhTPO at 3.6 µg/kg/dose on Days -5, -3, -1, and post-chemotherapy rhTPO on Days +4, +6, and +8 (6 doses total. Subsequent courses of chemotherapy will begin as soon as the ANC recovers to
= 1,000/µL and the platelet count to = 100,000/µL between days 21 and 35. Therapy will continue for maximum six courses. Pharmacokinetic data will be obtained (during course one nly). For the second cohort, full data collection will occur for cycles one and two and limited data collection for cycles 3, 4, 5, and 6.


Other interventions: recombinant human thrombopoietin


Treatment: Drugs: carboplatin


Treatment: Drugs: etoposide


Treatment: Drugs: ifosfamide


Other interventions: G-CSF
Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Determine the pharmacokinetics and toxicities associated with the administration of recombinant human thrombopoietin (rhTPO)
Timepoint [1] 0 0
length of study
Secondary outcome [1] 0 0
Evaluate the time for patients to demonstrate platelet recovery
Timepoint [1] 0 0
Length of study

Eligibility
Key inclusion criteria
DISEASE CHARACTERISTICS: Histologically proven (except for brain stem tumors) malignancy
that has

failed or relapsed after standard first-line antineoplastic therapy

- Sarcoma (soft tissue and bone)

- Kidney tumors

- Brain tumors

- Other solid tumors (gonadal and germ cell tumors, malignant melanoma,

- retinoblastoma, liver tumors, and miscellaneous tumors) Must have had recurrence
within the past 4 weeks

No bone marrow involvement

No prior or concurrent myelogenous leukemia

PATIENT CHARACTERISTICS:

Age:

- 1 to 21

Performance status:

- Lansky or Karnofsky 60-100%

Life expectancy:

- At least 12 weeks

Hematopoietic:

- Absolute neutrophil count greater than 1000/mm3

- Platelet count greater than 100,000/mm3

- No grade III or IV thrombosis

Hepatic:

- Bilirubin less than 1.5 times upper limit of normal (ULN)

- SGOT or SGPT less than 2.5 times ULN

Renal:

- Creatinine clearance or glomerular filtration rate at least 70 mL/min

Cardiovascular:

- Ejection fraction normal

- No evidence of arrhythmias requiring therapy

- Fractional shortening greater than 28%

Other:

- Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- At least 10 days since prior colony-stimulating factor therapy and recovered

- At least 30 days since prior epoetin alfa

- No other concurrent cytokines, including epoetin alfa

Chemotherapy:

- At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas) and

- recovered

- At least 3 months since therapy with etoposide, carboplatin, or ifosfamide

- that is identical to study treatment

Endocrine therapy:

- Not specified

Radiotherapy:

- Concurrent radiotherapy allowed after third course of therapy

- No prior cranial/spinal radiotherapy

- No prior radiotherapy to greater than 50% of bone marrow

Surgery:

- Concurrent surgery allowed after the second course of therapy

Other:

- No concurrent investigational agents

- No concurrent lithium, aspirin, coumadin, or heparin
Minimum age
1 Year
Maximum age
21 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria

Study design
Purpose of the study
Supportive Care
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/11/1998
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/09/2005
Sample size
Target
Accrual to date
Final
16
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 0 0
Princess Margaret Hospital for Children - Perth
Recruitment postcode(s) [1] 0 0
6001 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
District of Columbia
Country [3] 0 0
United States of America
State/province [3] 0 0
Indiana
Country [4] 0 0
United States of America
State/province [4] 0 0
Michigan
Country [5] 0 0
United States of America
State/province [5] 0 0
Minnesota
Country [6] 0 0
United States of America
State/province [6] 0 0
Missouri
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
Ohio
Country [9] 0 0
United States of America
State/province [9] 0 0
Pennsylvania
Country [10] 0 0
United States of America
State/province [10] 0 0
Tennessee
Country [11] 0 0
United States of America
State/province [11] 0 0
Texas
Country [12] 0 0
United States of America
State/province [12] 0 0
Utah
Country [13] 0 0
United States of America
State/province [13] 0 0
Washington
Country [14] 0 0
United States of America
State/province [14] 0 0
Wisconsin

Funding & Sponsors
Primary sponsor type
Other
Name
Children's Oncology Group
Address
Country
Other collaborator category [1] 0 0
Government body
Name [1] 0 0
National Cancer Institute (NCI)
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Colony-stimulating factors such as thrombopoietin and G-CSF may
increase the number of immune cells found in bone marrow or peripheral blood and may help a
person's immune system recover from the side effects of chemotherapy.

PURPOSE: Phase I trial to study the effectiveness of colony-stimulating factors in treating
children who have recurrent or refractory solid tumors and who are receiving chemotherapy.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00003597
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Mitchell S. Cairo, MD
Address 0 0
Herbert Irving Comprehensive Cancer Center
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00003597